August 26, 2021 10:40 AM EDTUpdated 11:02 AM

Amneal touts results from Phase III trial in Parkinson's; NovaRock partners on cancer drug

Paul Schloesser

Associate Editor

John Carroll

Editor & Founder

Amneal Pharmaceuticals announced positive results yesterday from a pivotal Phase III clinical trial that evaluated IPX-203 in patients with Parkinson’s disease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amneal touts results from Phase III trial in Parkinson's; NovaRock partners on cancer drug

Paul Schloesser

Associate Editor

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Am­neal touts re­sults from Phase III tri­al in Parkin­son's; No­vaRock part­ners on can­cer drug

Associate Editor

Editor & Founder

Sign up to read this article for free.

more like this

Amneal touts results from Phase III trial in Parkinson's; NovaRock partners on cancer drug